这是一项在中国儿童癌症协作组（CCCG）内进行的前瞻性、多中心研究。本研究旨在评估加入三种新型药物 dasatinib、venetoclax 及 homoharringtonine 能否提高新确诊T细胞急性淋巴细胞白血病（T-ALL）儿童患者的微量残留病灶（MRD）阴性缓解率、改善无事件生存期（EFS）及降低累积复发发生率（CIR）
适应症：Acute Lymphoblastic Leukemia、Childhood Leukemia, Acute Lymphoblastic、T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
入组条件
纳入标准
- Age older than 1 month to younger than 18 years.
- Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
- Diagnosis of T-ALL by immunophenotyping.
排除标准
- B-ALL
- Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.
- ALL evolved from chronic myeloid leukemia (CML).
- Down's syndrome, or major congenital or hereditary disease with organ dysfunction
- Secondary leukemia
- Known underlying congenital immunodeficiency or metabolic disease
- Congenital heart disease with cardiac insufficiency.
- Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
- Severe malnutrition, active infections, heart failure, or chemotherapy intolerance.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。